Hyperthermia, either alone or in combination with anticancer drugs, is becoming more and more a clinical reality for the treatment of far advanced gastrointestinal cancers, acting as a cytotoxic agent at a temperature between 40-42.5 degrees C. Although hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is demonstrated to have some benefit in selected patients with peritoneal seeding, there are not enough data on the risk of damage of normal tissue that increases as the temperature rises, with possible serious and, sometimes, lethal complications.
|Number of pages||6|
|Journal||European Review for Medical and Pharmacological Sciences|
|Publication status||Published - 2012|
- Antineoplastic Agents
- Combined Modality Therapy
- Hyperthermia, Induced
- Peritoneal Neoplasms